Topdanmark 2014 Half-Year Report 19 August 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Topdanmark 2014 Half-Year Report

19 August 2014
Announcement No. 10/2014

Key features

H1 2014

  • Post-tax profit of DKK 945m (H1 2013: DKK 784m)
  • EPS increased from DKK 6.5 to DKK 8.6
  • Combined ratio improved to 85.9% (H1 2013: 88.2%). Excluding run-off profits it improved to 89.7% (H1 2013: 91.6%)
  • Premium growth was 3.1% in non-life insurance and 29.0% in life insurance
  • Profit on life insurance declined to DKK 136m (H1 2013: DKK 238m). In H1 2013 DKK 118m was transferred from the shadow account, while in H1 2014 DKK 12m was transferred to the shadow account
  • Investment return increased to DKK 539m (H1 2013: DKK 326m).

Q2 2014

  • Post-tax profit: DKK 527m (Q2 2013: DKK 279m)
  • EPS:DKK 4.8 (Q2 2013: DKK 2.3)
  • Combined ratio: 82.4% (Q2 2013: 86.8%)
  • Combined ratio excluding run-off profits: 87.4% (Q2 2013: 89.3%)
  • Premium growth: Non-life insurance 2.8% and life insurance 35.6%
  • Profit on life insurance: DKK 62m (Q2 2013: DKK 29m)
  • Investment return: DKK 261m (Q2 2013: DKK 75m).

Profit forecast model for 2014

  • Topdanmark continues to assume premium growth of 2-3% for non-life insurance. In life insurance the assumption of a 0-5% growth in regular premiums also remains unchanged
  • Assumed combined ratio has been adjusted from 90-91% to around 89%, excluding run-off profits / losses in H2 2014
  • Post-tax profit forecast model for 2014 has been upgraded from DKK 1,150-1,250m to DKK 1,300-1,400m, excluding run-off profits / losses in H2 2014
  • Post-tax profit forecast model for 2014 represents EPS of DKK 12.5.

Share buy-back

  • The share buy-back programme for 2014 has been upgraded by DKK 150m to DKK 2,050m, representing a buy-back yield of 11.3%
  • Topdanmark has bought back own shares of DKK 1,010m in 2014, which leaves a balance of DKK 1,040m of the 2014 buy-back programme.

Webcast

In a webcast Topdanmark's CEO, Christian Sagild, presents the financial highlights and comments on the forecast. 

Conference call

A conference call will be held today at 15:30 (CET) when Christian Sagild, CEO, and Lars Thykier, CFO, will be available for questions based on the half-year report and the webcast. The call will be conducted in English.

In order to participate in the conference call, please phone:
UK dial in number: : +44 (0)20 7162 0125
US dial in number: +1 334 323 6203
10-15 minutes before the conference quoting reference 947148 and ask the operator to connect you to the Topdanmark conference call – or listen to the live transmission of the call.

Please direct any queries to:

Christian Sagild, Chief Executive Officer,
Direct tel.: +45 4474 4450

Lars Thykier, Chief Financial Officer,
Direct tel.: +45 4474 3714

Steffen Heegaard, Group Communications and IR Director,
Direct tel.: +45 4474 4017, mobile: +45 4025 3524

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading

Top 5 Most Recently Viewed Articles

Coke Florida's Commitment to Coastal Cleanliness Shines Bright

Updated Category News Views 141

Coke Florida's Volunteer Contributions for Coastal Cleanup Day Coca-Cola Beverages Florida, LLC (Coke Florida) was excited to take part in the worldwide celebration of International Coastal Cleanup (ICC) Day. This initiative, which focuses on sustainability and building community resilience, encouraged employees across the company's vast market to unite for a meaningful...

Continue Reading
LifeMD's Growth Momentum: Strong Earnings and Legal Support

Updated Category News Views 96

LifeMD Maintains Buy Rating Amid Positive Developments BTIG has reaffirmed its support for LifeMD Inc (NASDAQ: LFMD) by maintaining a Buy rating and a price target of $12.00 for the company’s stock. This endorsement comes at a pivotal time as the company experiences recent developments in the ongoing legal proceedings regarding tirzepatide, a drug used for treating type...

Continue Reading
Innovative Electric Heating Pad Adapter Set to Transform Comfort

Updated Category News Views 120

Innovative Heating Pad Adapter for Vehicles Inventors continuously strive to enhance daily experiences, and one such innovation is set to revolutionize comfort during travel. An inventor, inspired by the need for warmth while driving, developed the RIDE ALONG PRONG PLUG IN, a unique electric heating pad adapter accessible through a vehicle's cigarette lighter socket....

Continue Reading
Hang Feng Capital's Innovations Shine at Asia’s FinTech Hub

Updated Category News Views 158

Hang Feng Capital Excels at Hong Kong FinTech Week Recently, a remarkable event unfolded in the heart of Asia's financial landscape as Hang Feng Capital showcased its innovations during Hong Kong FinTech Week. Co-hosted by the local government and InvestHK, this pivotal event brought together over 700 exhibitors, 800 speakers, and an impressive crowd of 37,000 attendees...

Continue Reading
Autoliv Inc. Adjusts Revenue Forecast Amid Changing Market

Updated Category News Views 60

Autoliv Inc. got slapped with a serious reality check back in 2024 when JPMorgan revised its price target to $119, up just a hair from $117. You could feel the desks twitching as analysts dove into the automotive safety systems market, flagging Autoliv’s shaky standing amidst some forecasted storms brewing on the horizon. Global light vehicle production was supposed to...

Continue Reading